Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NV1066
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intraperitoneal
01
Overview
NV1066 is a replication-competent, attenuated oncolytic herpes simplex virus type 1 (HSV-1) engineered for the treatment of various solid tumors. It is characterized by deletions in the γ134.5 (ICP34.5) and ICP47 genes, which restrict viral replication to neoplastic cells and enhance the presentation of viral and tumor antigens. NV1066 is further modified to express the enhanced green fluorescent protein (eGFP) for tracking viral distribution and the viral thymidine kinase (TK) gene. The expression of TK allows for a synergistic "bystander effect" when administered alongside the prodrug ganciclovir, as the activated drug can spread to neighboring uninfected cells via gap junctions or tunneling nanotubes, inducing apoptosis in non-infected recipient cells.
- Other names
- NV 1066NV1066NV-1066HSV-1 NV1066HSV1 NV1066HSV 1 NV1066
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))NECTIN1 (Poliovirus receptor-related 1)HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))TMEFF2
Beyond the preview
Go deeper on NV1066.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NV1066.